Accord Receives Positive EMA Opinion for Two Denosumab Biosimilars
By EsqSocial Corporation 08/04/25
On April 2, 2025, Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for two denosumab biosimilars: OSVYRTI and JUBEREQ. OSVYRTI is indicated for the treatment of certain types of osteoporosis and bone loss....
By: Goodwin